PARK CITY, Utah --(BUSINESS WIRE)--Apr. 16, 2021-- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on April 15, 2021 , the Compensation Committee of its Board of Directors granted to 17 new employees inducement stock options to purchase an aggregate of 50,785 shares of its common
PARK CITY, Utah --(BUSINESS WIRE)--Mar. 19, 2021-- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Compensation Committee of its Board of Directors granted inducement stock options, inducement performance restricted stock units ("PRSUs"), and inducement restricted stock units
- Olorinab investigated in three doses, 10 mg, 25 mg, and 50 mg, for abdominal pain associated with IBS-C & IBS-D - Trial did not meet primary endpoint in broad study population - Moderate to severe pain population at 50 mg showed statistically significant, clinically meaningful improvement vs
- Significant pipeline progress with potentially first- or best-in-class drug candidates - Strong cash position of $1.1 billion as of December 31, 2020 SAN DIEGO --(BUSINESS WIRE)--Feb. 23, 2021-- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial
SAN DIEGO --(BUSINESS WIRE)--Feb. 18, 2021-- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on February 15, 2021 , the Compensation Committee of its Board of Directors granted to eleven new employees inducement stock options to purchase an aggregate of 33,885 shares of its common
SAN DIEGO --(BUSINESS WIRE)--Feb. 16, 2021-- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its fourth quarter and full-year 2020 financial results and provide a corporate update on Tuesday, February 23, 2021 , after the close of the U.S. financial markets.
- Industry veteran Garry Neil , MD, named Board Chair - Nawal Ouzren, CEO of Sensorion named to Board SAN DIEGO --(BUSINESS WIRE)--Feb. 16, 2021-- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced changes to the Company’s Board of Directors. Garry Neil , MD, has been appointed Chair of the
– Evaluating 2 mg etrasimod in study participants with moderately-to-severely active ulcerative colitis (UC) – Topline data from ELEVATE UC 12 and UC 52 trials remain on track for Q1 2022 – Significant unmet need for safe and effective oral therapies in UC for patients with inadequate response,
SAN DIEGO --(BUSINESS WIRE)--Jan. 22, 2021-- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on January 15, 2021 , the Compensation Committee of its Board of Directors granted to five new employees inducement stock options to purchase an aggregate of 16,950 shares of its common
SAN DIEGO , Dec. 22, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi , the Company's President and Chief Executive Officer, is scheduled to present virtually at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 , at